MAPT and Alzheimer disease: While these anti-amyloid mAbs are currently approved in several countries, it still leaves a continued unmet need for new treatments to further prevent or slow disease progression, notably in individuals with preclinical AD.9, 10, 11 In AD, cognitive decline correlates with the burden of pathological Tau inclusions, species that are prone to seeded aggregation and extracellular spreading.12